The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 30, No. 5, pp. 507-513.
© 1996 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chisholm, M.
Right arrow Articles by Taylor, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chisholm, M.
Right arrow Articles by Taylor, A.

Research Articles

Acute management of cancer-related hypercalcemia

MA Chisholm, AL Mulloy, and AT Taylor

OBJECTIVE: To review the pathogenesis and pharmacologic treatment of acute hypercalcemia associated with malignancy. DATA SOURCES: A MEDLINE search (1966 to 1995) of the English-language literature pertaining to acute hypercalcemia was performed. Additional literature was obtained from reference lists of articles identified through the search. STUDY SELECTION AND DATA EXTRACTION: All articles discussing the etiology and medical management of cancer-related acute hypercalcemia were considered in this review. Clinical trials reporting efficacy and safety of antihypercalcemic agents were also included. Information selected in the review was based on the discretion of the authors. DATA SYNTHESIS: Hypercalcemia is a life-threatening disorder associated with malignancy. It occurs in approximately 10-20% of patients with cancer. A variety of medications have been used in the management of hypercalcemia including bisphosphonates, calcitonin, furosemide, gallium nitrate, glucocorticoids, NaCl 0.9%, and plicamycin. Each of these agents has been reviewed with consideration of pharmacologic mechanism of action, evaluation of clinical trials, recommended dosages, efficacy, safety, cost, and role in treating cancer-related acute hypercalcemia. CONCLUSIONS: Immediate management of cancer-related acute hypercalcemia to prevent death and provide symptomatic relief is warranted. Severity determined by symptoms, calcium concentrations, and the overall status of the patient are important considerations in selecting appropriate therapy. Although the specific role of individual agents may vary, hydration remains the cornerstone of therapy. NaCl 0.9%, calcitonin, and pamidronate disodium have established roles as dominant first-line agents for the management of acute hypercalcemia associated with malignancy.


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. D. Kraft, I. F. Btaiche, G. S. Sacks, and K. A. Kudsk
Treatment of electrolyte disorders in adult patients in the intensive care unit
Am. J. Health Syst. Pharm., August 15, 2005; 62(16): 1663 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Zannetti, S. Del Vecchio, M. V. Carriero, R. Fonti, P. Franco, G. Botti, G. D’Aiuto, M. P. Stoppelli, and M. Salvatore
Coordinate Up-Regulation of Sp1 DNA-binding Activity and Urokinase Receptor Expression in Breast Carcinoma
Cancer Res., March 1, 2000; 60(6): 1546 - 1551.
[Abstract] [Full Text]

Home page
 J Oncol Pharm PractHome page
L. Nakashima
Guidelines for the treatment of hypercalcemia associated with malignancy
Journal of Oncology Pharmacy Practice, March 1, 1997; 3(1): 31 - 37.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1996 by Harvey Whitney Books Company.